Pfizer Invests in Molecular Glue Research; Jazz's Zepzelca Shows Promise in Lung Cancer
Key Insights
Pfizer has invested $49 million in Triana Biomedicines (search) to discover novel molecular glue degraders for oncology (search), with Pfizer holding an exclusive option to license promising candidates.
Jazz Pharmaceuticals' Zepzelca, combined with Roche's Tecentriq, demonstrated improved overall survival and progression-free survival in small cell lung cancer (search) patients in the IMforte Phase 3 study.
MeiraGTx's experimental gene therapy for Parkinson's disease (search) met its primary endpoint in a small clinical trial, showing safety and tolerability, with encouraging signs of efficacy.
Pfizer has entered into a research collaboration with Triana Biomedicines (search), investing $49 million to explore the development of novel molecular glue degraders for various disease areas, with an initial focus on oncology (search). Molecular glue degraders function by linking a protein target to cellular enzymes, marking the protein for degradation.
Pfizer's Molecular Glue Collaboration
Triana Biomedicines (search), based in Lexington, Massachusetts, will identify promising degrader candidates. Pfizer will then have an exclusive option to license these candidates for further development and potential commercialization in oncology (search). This collaboration highlights the growing interest in molecular glue degraders as a therapeutic modality, with potential applications across a range of diseases.
Jazz Pharmaceuticals' Zepzelca in Small Cell Lung Cancer
Jazz Pharmaceuticals announced positive results from the Phase 3 IMforte study, evaluating Zepzelca (lurbinectedin) in combination with Roche's Tecentriq (atezolizumab) as maintenance therapy for patients with small cell lung cancer (search) (SCLC). The combination therapy demonstrated statistically significant improvements in both overall survival (OS) and progression-free survival (PFS) compared to Tecentriq alone. Jazz plans to seek FDA approval for an expanded indication based on these data.
The IMforte study results offer a potential new treatment option for SCLC patients, addressing a significant unmet need in this aggressive cancer (search). The trial's success could lead to a shift in the standard of care for maintenance therapy in SCLC.
MeiraGTx's Gene Therapy for Parkinson's Disease
MeiraGTx reported positive data from a clinical trial of its experimental gene therapy for Parkinson's disease (search). The therapy met its primary endpoint, demonstrating safety and tolerability without any serious adverse events related to the treatment. The trial also showed encouraging signs of efficacy, suggesting the potential for disease modification.
Alexandria Forbes, CEO of MeiraGTx, stated that these results will "underpin" discussions with regulatory agencies in the U.S., Europe, and Japan as the company prepares for a late-stage trial. The positive data represent a significant step forward in the development of gene therapies for Parkinson's disease (search), offering hope for a new approach to treating this debilitating condition.
Akeso Secures Funding for Global Expansion
Akeso (search), a China-based biotechnology company, has raised $250 million through a private stock offering to fund international trials of its pipeline of antibody drugs for cancer (search) and autoimmune diseases (search). This funding will support the global expansion of Akeso's clinical development programs.
The financing follows recent data showing that an Akeso (search)-discovered drug outperformed Merck & Co. (search)'s Keytruda (pembrolizumab) in a Phase 3 trial, further validating Akeso's research and development capabilities. With over $1 billion in cash on hand, Akeso is well-positioned to advance its pipeline and pursue global regulatory approvals.